S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
Grab Starbucks on the dip before coffee futures fall
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
Grab Starbucks on the dip before coffee futures fall
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
Grab Starbucks on the dip before coffee futures fall
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
A trial deciding if JetBlue can buy Spirit — and further consolidate the industry — nears its end
Grab Starbucks on the dip before coffee futures fall

Nektar Therapeutics Stock Price, News & Analysis (NASDAQ:NKTR)

$0.51
0.00 (0.00%)
(As of 12/5/2023 ET)
Compare
Today's Range
$0.50
$0.53
50-Day Range
$0.42
$0.61
52-Week Range
$0.41
$3.19
Volume
649,061 shs
Average Volume
4.16 million shs
Market Capitalization
$97.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Nektar Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.86 Rating Score
Upside/​Downside
485.9% Upside
$3.00 Price Target
Short Interest
Bearish
4.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$17,474 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.84) to ($0.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

270th out of 948 stocks

Pharmaceutical Preparations Industry

109th out of 421 stocks


NKTR stock logo

About Nektar Therapeutics Stock (NASDAQ:NKTR)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR Stock Price History

NKTR Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Positive Report for Nektar Therapeutics (NKTR) from TD Cowen
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Recap: Nektar Therapeutics Q3 Earnings
Nektar Therapeutics Q3 Loss decreases, but misses estimates
A Preview Of Nektar Therapeutics's Earnings
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
Nektar Therapeutics Q2 Loss decreases, beats estimates
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
216
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$6.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+485.9%
Consensus Rating
Reduce
Rating Score (0-4)
1.86
Research Coverage
7 Analysts

Profitability

Net Income
$-368,200,000.00
Net Margins
-332.73%
Pretax Margin
-329.36%

Debt

Sales & Book Value

Annual Sales
$92.06 million
Book Value
$1.95 per share

Miscellaneous

Free Float
184,914,000
Market Cap
$97.67 million
Optionable
Optionable
Beta
0.88

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Howard W. RobinMr. Howard W. Robin (Age 70)
    CEO, President & Director
    Comp: $1.83M
  • Mr. Mark A. Wilson (Age 51)
    Senior VP, Chief Legal Officer & Secretary
    Comp: $749.99k
  • Dr. Jonathan Zalevsky Ph.D. (Age 48)
    Senior VP & Chief Research and Development Officer
    Comp: $1.25M
  • Ms. Sandra A. Gardiner (Age 57)
    Chief Financial Officer
  • Vivian Wu
    Director of Investor Relations & Corporate Affairs
  • Mr. Robert Bacci
    Senior Vice President of Human Resources & Facilities Operations
  • Ms. Jennifer Ruddock
    Chief Business Officer
  • Dr. Mary Tagliaferri L.Ac. (Age 57)
    M.D., Chief Medical Officer
  • Dr. Loui T. Madakamutil
    VP and Head of Discovery & Research














NKTR Stock Analysis - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 sell ratings, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" NKTR shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price target for 2024?

7 brokerages have issued 1-year price targets for Nektar Therapeutics' stock. Their NKTR share price targets range from $1.00 to $6.00. On average, they anticipate the company's share price to reach $3.00 in the next year. This suggests a possible upside of 485.9% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2023?

Nektar Therapeutics' stock was trading at $2.26 at the start of the year. Since then, NKTR shares have decreased by 77.3% and is now trading at $0.5120.
View the best growth stocks for 2023 here
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) issued its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03. The biopharmaceutical company had revenue of $20.50 million for the quarter, compared to the consensus estimate of $20.94 million. Nektar Therapeutics had a negative net margin of 332.73% and a negative trailing twelve-month return on equity of 80.44%. During the same period in the previous year, the firm posted ($0.85) EPS.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (9.80%), Acadian Asset Management LLC (4.00%), Primecap Management Co. CA (3.77%), Jacobs Levy Equity Management Inc. (2.57%), Monaco Asset Management SAM (2.53%) and AQR Capital Management LLC (1.92%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, Robert Chess and Roy A Whitfield.
View institutional ownership trends
.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NKTR) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -